Phase I Dose Escalation and Cohort Expansion Study of LB-208, a HTR1B Antagonist, in Adults with Relapsed or Refractory Solid Tumors and Lymphoma

The primary objective of this study is to evaluate the safety and tolerability of **LB-208**, a **HTR1B antagonist**, in adult patients with relapsed or refractory **solid tumors** and **lymphoma**. This is a first-in-human, dose escalation and cohort expansion study, which is crucial for determining the appropriate dosage and understanding the potential adverse effects of LB-208 in this patient population. The clinical relevance of this study lies in its potential to offer a new therapeutic option for patients with limited treatment alternatives due to the relapsed or refractory nature of their conditions.

The clinical trial involves participants diagnosed with **lymphoma** or a **solid tumor**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically encompass adults and older adults. The trial population selection criteria include individuals from a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and specific inclusion or exclusion criteria are not detailed in the available data.

The clinical trial is a **Phase 1** study designed to evaluate the safety, tolerability, and preliminary efficacy of LB-208, a **HTR1B antagonist**, in adult patients with relapsed or refractory **lymphoma** and **solid tumors**. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from June 2024, with the recruitment start date, to August 2027, marking the anticipated end date. Participants will be involved in the study for a period that aligns with the trial's progression through dose escalation and cohort expansion phases.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. This is followed by a series of follow-up visits, which are scheduled at regular intervals to monitor the participants' response to the treatment and to collect data on safety and efficacy endpoints. The end-of-study visit marks the conclusion of a participant's involvement, where final assessments are conducted to gather comprehensive data on the long-term effects of the investigational product.

Participants are expected to remain in the study for its entire duration unless specific conditions necessitate early termination. Such conditions may include adverse events that compromise participant safety, withdrawal of consent, or any other protocol-defined criteria that warrant discontinuation. The trial is structured to ensure that all procedures are conducted in accordance with ethical standards and regulatory requirements, providing a robust framework for evaluating the investigational product's potential benefits and risks.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the pharmaceutical form, maximum daily dose, maximum total dose, or maximum treatment period of the experimental medication. Furthermore, there is no information regarding whether the formulation is pediatric or if the product is classified as an **orphan drug**.

As the source data lacks comprehensive details about the trial's treatments, this description remains limited to the information provided. For a complete understanding of the clinical trial's treatments, further details from the trial protocol or investigator brochure would be necessary.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is June 3, 2024, with an anticipated end date of August 2, 2027. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. The trial will likely employ standardized methods for data collection and analysis, consistent with clinical research protocols. The absence of detailed endpoints suggests that the trial may focus on exploratory outcomes, which are common in early-phase studies. The trial's design will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments conducted throughout the study period.